news
Antalis drives forward with new vehicle fleet
Antalis’ customers are set to benefit from a fleet of more technologically advanced vehicles as part of its £5m partnership with fleet provider, Fraikin...
List view / Grid view
Outsourcing
article
Outsourcing: Current trends in the CDMO sector
Patheon’s Joe Principe examines current trends in outsourcing, highlighting the importance of investment in CDMO partnerships...
news
Thermo Fisher to acquire Patheon in $7.2bn deal
Thermo Fisher Scientific announced yesterday that it would buy contract development and manufacturing organisation (CDMO) Patheon for $7.2bn...
article
Alliance management organisational development: A Bayer perspective
4 April 2017 | By Christoph Huwe, Strategic Alliance Manager Therapeutics at Bayer Pharmaceuticals, Global External Innovation & Alliances
Ahead of the 7th Annual Strategic Alliance Management for Pharma conference, we spoke with Bayer's Christoph Huwe about the organisational development of alliance management...
article
An interview with Dr. Timothy S. Oostdyk, Eurofins
Dr. Timothy S. Oostdyk, Group Senior Vice President of Eurofins BioPharma Product Testing, discusses the issues affecting outsourcing to the biopharmaceutical industry and the benefits of having a wide global reach...
news
CPhI report highlights potential risks in biologics supply chain outsourcing
15 October 2015 | By Victoria White
CPhI highlights these risks in the fourth and final section of its 2015 annual report, The Outsourcing perspective...
news
Batavia Bioservices changes name to Batavia Biosciences
Batavia Bioservices has changed its name to Batavia Biosciences as of 23 April 2015. The change will coincide with the launch of a new website and multimedia communication strategy.
article
Outsourcing in the analytical and microbiology area
20 April 2015 | By Roger A. Stroud, R Stroud Pharmaceutical Quality Solutions Limited
Increasing numbers of pharmaceutical companies are considering outsourcing in the area of analytical and microbiological testing, from the very smallest start-up, virtual, or small company up to the largest multinational. This article will examine the factors that lead to a company deciding to outsource, and provides invaluable guidance on the…
article
Eurofins BioPharma product testing laboratories
23 December 2014 | By Eurofins BioPharma
The largest network of harmonised bio/pharmaceutical gross manufacturing product (GMP) testing laboratories worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through to commercialisation while ensuring regulatory compliance, cost effectiveness and achievement of timelines...
news
Big bio/pharma would rather ‘make than buy,’ says PharmSource
Leader in contract bio/pharma industry intelligence predicts ongoing in-house manufacture...
product
Product Hub: Eurofins BioPharma Product Testing
15 April 2014 | By European Pharmaceutical Review
Timothy S. Oostdyk, PhD, President of Eurofins Lancaster Laboratories; Sr. Vice President, Eurofins BioPharma Product Testing Group, discusses harmonising policies, quality and services among 14 global facilities.
news
Is Big Pharma still actively engaging in outsourcing?
19 February 2014 | By Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc
Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc answers the question “From a vendor perspective, do you conclude that Big Pharma is still actively engaging in outsourcing of the activities that you have expertise in?”
article
Evolving landscape of pharmaceutical outsourcing in China
22 October 2012 | By Xiaorong He, Senior Research Fellow, Boehringer-Ingelheim
China’s economic growth has shocked and awed the world, with its GDP growing at an average rate of 10 per cent for 30 years. The astonishing economic growth has also spurred rapid growth of pharmaceutical outsourcing business in China. In the past, China had been the major source of raw…
article
Discovery chemistry outsourcing
26 April 2012 | By Luigi La Vecchia, Director of the Preparations Laboratories, Novartis Institute for Biomedical Research
In 2002, Novartis decided to create a new research centre in Cambridge, MA. This was accompanied by a significant increase in headcount in medicinal chemistry. Within two years, this resulted in a strongly increased demand for prep-scale synthesis which in turn led to priority issues and to prolonged turnaround times…
article
Outsourcing in early drug discovery: Evolution and opportunities
26 April 2012 | By Jayshree Mistry, Paul Lloyd, Kevin Oliver and Peter North, GlaxoSmithKline R&D and Duncan Judd, Awridian
This article describes the evolution of outsourcing within early drug discovery at GlaxoSmithKline (GSK), specifically for chemistry services applied to developing a compound from the screening hit through lead optimisation. It will touch on different business models, factors to consider when selecting potential CROs, the benefits of outsourcing and CRO…
